Craig M. van de Mark

ZZ Biotech LLC operates as a clinical stage company. It develops biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. The firm mainly focuses on developing 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. The company was founded by Selim Zilkha and Berislav V. Zlokovic in 2006 and is headquartered in Houston, TX.

ZZ Biotech LLC operates as a clinical stage company. It develops biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. The firm mainly focuses on developing 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. The company was founded by Selim Zilkha and Berislav V. Zlokovic in 2006 and is headquartered in Houston, TX.

ZZ Biotech LLC operates as a clinical stage company. It develops biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. The firm mainly focuses on developing 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. The company was founded by Selim Zilkha and Berislav V. Zlokovic in 2006 and is headquartered in Houston, TX.

ZZ Biotech LLC operates as a clinical stage company. It develops biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. The firm mainly focuses on developing 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. The company was founded by Selim Zilkha and Berislav V. Zlokovic in 2006 and is headquartered in Houston, TX.

ZZ Biotech LLC operates as a clinical stage company. It develops biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. The firm mainly focuses on developing 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. The company was founded by Selim Zilkha and Berislav V. Zlokovic in 2006 and is headquartered in Houston, TX.